Table 3.
Reproductive outcomes of IVF cycles in aPL positive women before and after hydroxychloroquine and antiplatelets treatment.
IVF laboratory outcomes | Agonist protocol | Antagonist protocol | PPOS protocol | ||||||
---|---|---|---|---|---|---|---|---|---|
Before treatment (n=23) | After treatment (n=21) | p-value | Before treatment (n=8) | After treatment (n=8) | p-value | Before treatment (n=13) | After treatment (n=12) | p-value | |
Days of ovarian stimulation | 11.8 ± 2.0 | 11.4 ± 2.3 | 0.649 | 9.0 ± 2.6 | 10.0 ± 1.2 | 0.454 | 10.1 ± 3.1 | 9.8 ± 2.6 | 0.776 |
Total Gn dose (IU) | 2310.0 ± 1103.5 | 2525.0 ± 1297.0 | 0.681 | 1875.0 ± 826.7 | 1743.8 ± 824.7 | 0.818 | 2127.0 ± 889.1 | 2131.3 ± 646.3 | 0.804 |
Retrieved oocytes | 12.1 ± 6.3 | 13.1 ± 6.1 | 0.662 | 8.6 ± 3.7 | 11.3 ± 7.9 | 0.433 | 5.0 ± 3.5 | 6.7 ± 4.6 | 0.341 |
M II oocytes rate (%) | 67.1 ± 24.0 | 74.8 ± 17.6 | 0.236 | 64.5 ± 26.1 | 83.2 ± 34.1 | 0.271 | 74.3 ± 18.0 | 85.1 ± 14.8 | 0.112 |
Normal fertilization rate (%) | 56.0 ± 27.1 | 72.1 ± 15.1 | 0.026 | 54.1 ± 25.5 | 64.1 ± 19.5 | 0.462 | 63.8 ± 25.1 | 75.1 ± 20.5 | 0.229 |
Embryos | 7.8 ± 4.1 | 8.8 ± 3.0 | 0.525 | 5.4 ± 3.5 | 7.6 ± 4.4 | 0.335 | 3.1 ± 1.9 | 5.5 ± 3.7 | 0.062 |
Perfect embryos | 2.5 ± 1.8 | 5.4 ± 1.8 | 0.000 | 1.9 ± 1.2 | 5.1 ± 3.1 | 0.022 | 1.7 ± 2.6 | 3.2 ± 2.6 | 0.143 |
Available embryos | 4.1 ± 3.0 | 6.8 ± 3.1 | 0.034 | 2.6 ± 1.7 | 6.3 ± 3.0 | 0.015 | 2.6 ± 4.5 | 4.4 ± 4.0 | 0.300 |
Blastocyst formation rate (%) | 22.5 ± 22.7 | 41.0 ± 14.7 | 0.004 | 20.2 ± 14.5 | 36.4 ± 14.7 | 0.125 | 16.3 ± 17.4 | 22.5 ± 20.5 | 0.426 |
Perfect embryo rate (%) | 38.1 ± 23.2 | 65.6 ± 13.8 | 0.003 | 47.3 ± 38.3 | 77.3 ± 23.3 | 0.102 | 21.7 ± 24.2 | 61.8 ± 31.1 | 0.002 |
Available embryo rate (%) | 53.2 ± 31.3 | 80.0 ± 16.0 | 0.000 | 60.0 ± 37.1 | 98.8. ± 18.1 | 0.035 | 36.3 ± 37.8 | 77.8 ± 29.2 | 0.005 |
aPL, antiphospholipid antibody, such as anti-cardiolipin antibody and/or β2-glycoprotein-I antibody. P-value <0.05 was considered to be statistically significant.